Physician profile
Roushanak Fadavi
NPI 1891033825
$6,366.88
in general payments reported to CMS, 2019-2025
23 companies · $2,455 in 2025
The $2,455 reported for 2025 was more than what 94% of Corneal and Contact Management providers received nationally (typical 2025 total: $227).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $351 · 2020: $132 · 2021: $547 · 2022: $523 · 2023: $1,517 · 2024: $842 · 2025: $2,455.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,814.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,814.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $1,312.83 | 2022-2025 | Miebo, Vyzulta, Xiidra |
| Dompe US, INC. | $854.18 | 2022-2025 | Oxervate |
| Sun Pharmaceutical Industries INC. | $847.74 | 2021-2025 | Cequa, Bromsite, Xelpros |
| Alcon Vision LLC | $698.58 | 2019-2025 | Tryptyr, Eysuvis, Rocklatan |
| Oyster Point Pharma, INC. | $323.50 | 2022-2025 | Tyrvaya |
| Tarsus Pharmaceuticals, INC. | $318.53 | 2025 | Xdemvy |
| Glaukos Corporation | $253.55 | 2021-2025 | Idosetr |
| Ocular Therapeutix, INC. | $216.56 | 2023-2025 | Dextenza |
| Sight Sciences, INC. | $193.66 | 2021-2023 | Omni Surgical System |
| Shire North American Group INC | $192.48 | 2019 | |
| Amgen INC. | $169.57 | 2025 | Tepezza |
| Aerie Pharmaceuticals, INC. | $154.71 | 2021 | |
| Mallinckrodt Hospital Products INC. | $147.90 | 2025 | Acthar |
| Allergan, INC. | $140.80 | 2022 | |
| Harrow Eye, LLC | $96.88 | 2024-2025 | Vevye, Ilevro |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rxsight INC | $83.25 | 2023 | Rxsight Injector Cartridge, Rxsight Contact Lens, Rxsight Injector Handpiece |
| Kala Pharmaceuticals, INC. | $79.99 | 2019 | |
| Novartis Pharmaceuticals Corporation | $64.95 | 2022-2023 | |
| Abbvie INC. | $63.37 | 2022-2023 | |
| Johnson & Johnson Surgical Vision, INC. | $56.51 | 2021-2022 | |
| Thea Pharma INC. | $44.62 | 2022 | |
| Johnson & Johnson Vision Care, INC. | $30.87 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $21.85 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roushanak Fadavi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.